Servier

GeNeuro is a biotechnology company based in Plan-Les-Ouates, Switzerland, specializing in the development of therapeutic drugs for diseases linked to pathogenic proteins originating from human endogenous retroviruses. The company primarily targets nervous system disorders, including multiple sclerosis and schizophrenia. Its lead product, GNbAC1, is a therapeutic monoclonal antibody designed to treat multiple sclerosis, while temelimab is another candidate that neutralizes a pathogenic protein from the HERV-W family. Additionally, GeNeuro is engaged in developing diagnostic tests to measure multiple sclerosis-associated retrovirus-ENV proteins in patients. Founded in 2006, the company is committed to addressing the underlying factors that drive the progression of neurodegenerative and autoimmune diseases.

Agios Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of medicines targeting cellular metabolism and related areas, including hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO, an oral targeted inhibitor for treating relapsed or refractory acute myeloid leukemia (AML) in adult patients, and IDHIFA, which is also aimed at AML patients with specific mutations. Agios is advancing several drug candidates through various stages of clinical trials, including TIBSOVO for frontline AML and cholangiocarcinoma, mitapivat for pyruvate kinase deficiency and thalassemia, and vorasidenib for solid tumors. The company emphasizes a precision medicine approach, focusing on genetically or biomarker-defined patient populations to enhance the potential for early proof of concept and accelerated approval. Agios Pharmaceuticals was established in 2007 and has evolved from its original name, Cancer Metabolism Therapeutics, to its current identity.

Symphogen specializes in developing a novel class of biopharmaceuticals, recombinant polyclonal antibodies (rpAb), for treating and preventing serious diseases, with a focus on cancer and infectious diseases. Their pipeline includes rpAb compositions for treating idiopathic thrombocytopenic purpura, preventing hemolytic disease in newborns, and mitigating adverse reactions from smallpox vaccinations, aiming to facilitate prompt cancer treatment and improve patient outcomes.